The company has seen rapid growth and will be expanding into additional U.S. markets in 2023

Per Diem Staffing Platforms
Nurseio Quickly Becoming One of the Industry’s Most Widely Used Per Diem Staffing Platforms

PHOENIX – November 21, 2022 – (Newswire.com)

From its humble beginnings as a start-up, the Nurseio digital staffing platform has grown rapidly into a widely used solution for staffing per diem healthcare roles across the U.S.

The Nurseio platform was developed to provide healthcare professionals – including nurses, technicians, caregivers, and nursing assistants – with a convenient way to find and book shifts in their specialties. It has also served as a key alternative to traditional staffing agencies for healthcare facilities, many of which prefer the flexibility that comes with using a web-based app for filling PRN shifts with qualified workers.

Nurseio’s app can be used in a browser or on a smartphone via IOS or Android. In addition to convenience, the platform’s growth can be attributed in part to a need for such technology. For example, Nurseio makes it easier for facilities and professionals to post and fill shifts on demand, in turn, lending significant support to an industry that is often plagued by staffing shortages and worker burnout.

With Nurseio, there are no commitments to expensive staffing agencies, and facilities get personalized support 24/7 from the platform’s team. Meanwhile, healthcare professionals get complete control over their personal schedules, plus the ability to achieve the work-life balance they prefer while receiving premium pay delivered instantly to their bank account after every shift. RNs, LPNs, CNAs, and other professionals can opt for flexible work that fits their schedule and preferences, getting the support they need to prioritize what they value most.

In the year ahead, Nurseio expects to continue to grow and expand into markets across the United States. Currently, the platform has over 33,000 registered healthcare professionals looking for per diem shifts. Facilities are able to quickly fill these shifts by posting them onto Nurseio, where professionals who meet the qualifications and certifications they are looking for can then accept them. 

As Nursieo continues to grow, both healthcare facilities and professionals can expect to see additional opportunities available on the platform and even greater support for streamlining the staffing process. 

About Nurseio

Nurseio is a web and app-based platform that connects healthcare facilities and nursing professionals for PRN and per diem shift work. Through the app, facilities can post and fill open shifts and instantly connect with qualified workers who are ready to accept them, and healthcare professionals can take more control over their careers and work when, where, and how much they want.

Those who are interested in learning more about Nursieo are invited to visit Nurseio’s website, where additional information is available regarding the platform’s benefits and how it works.

Contact Information:

Callie Ott

Co-Founder and COO

[email protected]

Seth Courson

Co-Founder and CEO

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Nurseio Quickly Becoming One of the Industry’s Most Widely Used Per Diem Staffing Platforms

Safety Training Seminars provides American Heart Association CPR, BLS, ACLS, PALS, NRP, and First-aid training courses in San Jose, Morgan Hill, Santa Clara, and Los Gatos.

…

New chip releases large AI models from the cloud and runs them at low power in devices enabling full conversational dialog and complex AI inference inexpensively and at low power.

…

MUNICH – November 21, 2022 – (Newswire.com)

neurocare group AG (“neuroca…

State-of-the-art system of neural networks and machine learning models that transforms non-numeric healthcare provider voice responses at scale into measurable insights.

…

ANKARA, Turkey – November 20, 2022 – (Newswire.com)

Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile app Parky for monitoring Parkinson’s Disease. Parky App monitors symptoms such as tremors and dyskinesia in real-time via the use of the Apple Watch. It is a tool for sharing meaningful and reliable data between patients and medical professionals regarding the course of the disease.

The app leverages the Movement Disorder API, a tool developed by Apple. The API was validated in a study of 343 participants, including longitudinal tracking of 225 participants for up to six months and used the clinical gold standard (MDS-UPDRS) as a reference. Details of the study were published in Science Translational Medicine last year.

10 million patients worldwide live with Parkinson’s Disease, the fastest-growing neurological disorder. Healthcare professionals in this area need reliable feedback and data for optimized treatment plans. Parky App helps medical professionals to develop a clinical profile of the patient while outside of the clinic. The Parky App strengthens the possibility of data-driven, tailored treatment procedures and bridges the gap between real-life and in-clinic settings.

“As a woman-founded, non VC-backed company based in Turkey, receiving our first 510(k) clearance is a huge milestone for us. We believe Parky will bring great value to the Parkinson’s Disease community as an easily scalable and data-driven product,” Yagmur Selin Gulmus, the founder of h2o therapeutics, said in a statement. The company has 2 more digital therapeutics products in the pipeline based on wearable devices and FDA submissions are planned to be completed in 2023.

h2o therapeutics is developing digital therapeutics with a focus on mobile technologies, Augmented Reality (AR), and Artificial Intelligence (AI). h2O intends to make real-time human data become a handy tool for disease management in certain therapeutic areas. Their core understanding of digital therapeutics lies in the power of AI, the robustness of their clinical health research, and high levels of user engagement.

Contact Information:

Yagmur Selin Gulmus

Founder

[email protected]

Hande Erciyes

Operations Manager

[email protected]

Press Release Service
by
Newswire.com

Original Source:

H2o Therapeutics Gets FDA Clearance for Its Apple Watch-Based App for Parkinson’s Disease

Employees allege firing after religious exemptions to covid shot mandate were denied

BOSTON – Nove…

Altrua Ministries in Action

Altrua HealthShare + Jordan Feliz + Danny Gokey + Convoy of Hope Donation Presentation of check Danny Gokey and Jorda…

Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches “I Have Cancer,” a social media campaign to raise cancer awareness.

NEW YORK – November 17, 2022 – (Newswire.com)

In keeping with its mission to improve the lives of cancer patients, Massive Bio aims to raise mass awareness about cancer, cancer treatments, and clinical research with “I Have Cancer,” the company’s new social media campaign. “I Have Cancer” will focus on the problems experienced by cancer patients and their loved ones while bringing attention to the importance of cancer prevention. The campaign will also provide up-to-date information about oncology clinical trials for cancer patients interested in pursuing innovative new treatments. Massive Bio, based in New York City, uses a proprietary artificial intelligence platform called SYNERGY-AI to match cancer patients to clinical trials.

“This project is very important for society,” says Erkan Terzi, Global Marketing Vice President for Massive Bio and one of the architects of the “I Have Cancer” campaign. “We have cancer awareness, but the problem is how much we understand cancer and cancer patients. Millions of people die from cancer yearly, and everyone is at risk of getting cancer. With this project, we want to raise cancer awareness, show how we can protect ourselves and our loved ones, and provide information about cancer treatments.”

“Clinical milestones include working with physicians, pharmaceutical and genomic testing providers, and hospitals, as well as our network of oncology clinical trial registration opportunities in Europe and South America,” said Çağatay Çulcuoğlu, co-founder, CFO, and COO of Massive Bio. “We have expanded our patient-engagement activities through advocacy groups, webinars, and the publication of Massive Bio magazine, which informs readers about the latest news in cancer research and clinical trials. Now, with our ‘I Have Cancer’ campaign, we aim to be the voice of patients and their families who need support and are not heard but who want to share their experiences and ideas to build a better tomorrow for future generations.”

The “I Have Cancer” campaign, which will launch in November with posts on Massive Bio’s social media channels, will emphasize the theme that cancer patients are not alone. The importance of cancer foundations and associations will also be highlighted in the campaign, carried out simultaneously on Facebook, Instagram, TikTok, Twitter, LinkedIn, and YouTube. The campaign will use the hashtags #ihavecancer, #cancerawareness, and #massivebio to help cancer patients and their supporters make their voices heard. The campaign will continue until the end of May. 

About Massive Bio

Massive Bio’s mission is to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances. Massive Bio solves bottlenecks in recruiting patients for clinical trials with a unique technology-enabled service and big data platform. The company serves pharmaceutical companies, contract research organizations, and hospital networks with a focus on improving the lives of cancer patients and provides oncology-specific data-driven patient recruitment, site selection, and AI-based trial pre-screening services.

Contact Information:

merve sahin

PR Executive

[email protected]

+1 844 627 7246

Press Release Service
by
Newswire.com

Original Source:

Massive Bio Launches ‘I Have Cancer’ Campaign

U.S. hospitals and healthcare systems gain access to expanded toolset for driving compliance to CMS & OIG regulations.

SpendMend SpendMend
…